Immune Parameters in a Steroid Sparing Clinical Trial

类固醇节约临床试验中的免疫参数

• 批准号: 6611931
• 负责人: Nancy Louise Reinsmoen
• 金额: $ 30.47万
• 依托单位: DUKE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2002
• 资助国家: 美国
• 起止时间: 2002-09-30 至 2006-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6611931
• 关键词: FK506; adenosine triphosphate; antigen antibody reaction; antigens; antiidiotype antibody; artificial immunosuppression; clinical trials; creatinine; cyclosporines; enzyme linked immunosorbent assay; flow cytometry; human subject; human therapy evaluation; interferon gamma; kidney transplantation; mycophenolate mofetil; oxidative phosphorylation; patient oriented research; sirolimus; steroid hormone; transplant rejection; transplantation immunology

DESCRIPTION (provided by applicant): Studies of steroid withdrawal in selected low-risk recipients have been implemented to decrease the numerous post transplant side effects of steroids but have been associated with an increased rate of acute rejection. More recently, steroid avoidance immunosuppression protocols have been implemented. The short-term results show there is no increase in the rate of acute rejection; however, the long-term effects of these protocols on graft function and survival are not known. The current three-arm clinical trial of rapid discontinuation of prednisone at the University of Minnesota is designed to determine the best long-term steroid avoidance immunosuppressive protocol. Immune parameters are needed to investigate mechanisms of acute and chronic rejection and to determine if short- and long-term graft outcome can be predicted. Ideally, these immune parameters could identify recipients at high risk for acute, subacute, and chronic rejection. Our goal is to determine if measurement of pre- and post transplant responses to donor antigen can predict graft outcome, thereby allowing for individualization of immunosuppression and identifying potential points for intervention. The first specific aim is focused on investigating immune mechanisms involved in acute rejection using assays designed to determine if donor antigen-specific immune parameters, including ELISpot, intracellular ATP synthesis, and low levels of anti-HLA antibody can identify recipients at high risk for developing acute and sub-clinical rejection. The second specific aim, designed to study immune mechanisms associated with chronic rejection, outlines assays which test if donor antigen-specific direct and indirect recognition of donor antigen/peptides in ELISpot and flow cytometric assays can identify recipients at high risk for developing chronic rejection. Studies of the third specific aim are designed to determine if the measurement of intracellular ATP synthesis can accurately measure the immune response in the presence of the combined immunosuppressive reagents and can predict over-immunosuppression. These studies are important to quickly alert clinicians to any changes in immune status and overall response to the three immunosuppression regimes. Thus, the overall study is designed to use immune parameters to identify recipients at low vs. high risk for poor graft outcome, thereby allowing for individualization of immunosuppression aimed at improving long-term graft outcome.

描述（由申请人提供）：在选定的低风险接受者中进行类固醇停药研究，以减少类固醇的许多移植后副作用，但与急性排斥反应率增加有关。最近，已经实施了类固醇避免免疫抑制方案。短期结果显示，急性排斥反应的发生率没有增加;然而，这些方案对移植物功能和存活的长期影响尚不清楚。目前在明尼苏达大学进行的快速停用泼尼松的三组临床试验旨在确定最佳的长期类固醇避免免疫抑制方案。需要免疫参数来研究急性和慢性排斥反应的机制，并确定是否可以预测短期和长期的移植结果。理想情况下，这些免疫参数可以识别急性，亚急性和慢性排斥反应的高风险受体。我们的目标是确定移植前和移植后对供体抗原的反应的测量是否可以预测移植结果，从而允许个体化的免疫抑制和确定潜在的干预点。第一个具体的目标是集中在调查免疫机制参与急性排斥反应，使用旨在确定供体抗原特异性免疫参数，包括ELISpot，细胞内ATP合成，和低水平的抗HLA抗体的测定可以识别收件人在发展急性和亚临床排斥反应的高风险。第二个具体目标，旨在研究与慢性排斥反应相关的免疫机制，概述了检测ELISpot和流式细胞术检测中供体抗原特异性直接和间接识别供体抗原/肽是否可以识别慢性排斥反应高风险受体的检测方法。第三个特定目的的研究旨在确定细胞内ATP合成的测量是否可以准确测量联合免疫抑制剂存在下的免疫应答，并可以预测过度免疫抑制。这些研究对于快速提醒临床医生免疫状态的任何变化和对三种免疫抑制方案的总体反应非常重要。因此，整个研究旨在使用免疫参数来识别移植物结局不良的低风险与高风险受体，从而允许个体化免疫抑制，旨在改善长期移植物结局。